Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Treatment of Dialysis-Related Amyloidosis Using Lixelle® β2-microglobulin Apheresis Column
Sponsor: Kaneka Medical America LLC
This NA trial investigates Dialysis Amyloidosis and is currently actively recruiting participants. Kaneka Medical America LLC leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Recruiting NA
-
Apr 2025 — May 2025 [monthly]
Recruiting NA
-
Sep 2024 — Apr 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Nov 2023 — Mar 2024 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Oct 2021 — Nov 2023 [monthly]
Unknown Status NA
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status NA
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2017 — Apr 2019 [monthly]
Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kaneka Medical America LLC
For direct contact, visit the study record on ClinicalTrials.gov .